SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-161593
Filing Date
2023-06-06
Accepted
2023-06-06 16:02:00
Documents
12
Period of Report
2023-05-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d480804d8k.htm   iXBRL 8-K 29241
  Complete submission text file 0001193125-23-161593.txt   154996

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tsha-20230531.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20230531_lab.xml EX-101.LAB 18737
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20230531_pre.xml EX-101.PRE 11703
6 EXTRACTED XBRL INSTANCE DOCUMENT d480804d8k_htm.xml XML 3468
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 23996048
SIC: 2836 Biological Products, (No Diagnostic Substances)